IBRAHIM, M. M.; Li, C.; Yinzhong, M.; Fang, C.

Sepsis is a life-threatening condition driven by dysregulated immune responses and multi-organ dysfunction, with limited treatments targeting its underlying pathophysiology. Growing evidence highlights fatty acid-binding protein 4 (FABP4) as a key mediator of inflammation and organ injury in sepsis. In this study, we investigated the therapeutic potential of an anti-FABP4 monoclonal antibody (6H2) in a murine endotoxemia model induced by lipopolysaccharide (LPS). Treatment with 6H2 significantly attenuated systemic inflammation, as evidenced by modulated leukocyte responses, and provided substantial tissue protection in the liver, lungs, kidneys, and heart, reducing histopathological damage. Our findings identify 6H2 as a promising novel therapeutic intervention for sepsis.